|
|
Article: Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL™ DosePro™.
- Article from:
- Biotech Week
- Article date:
- November 11, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, and Desitin Pharmaceuticals GmbH ("Desitin"), a privately held, mid-sized German pharmaceutical company, announced that Desitin has filed for European regulatory approval of SUMAVEL DosePro (sumatriptan injection) needle-free delivery system. The announcement follows successful completion of a European pivotal bioequivalence trial comparing needle-free SUMAVEL DosePro to a traditional needle-based autoinjector, Imigran=AE-Inject, the European brand of Imitrex STATdose System=AE. In March 2008, Zogenix and Desitin entered into a license agreement granting exclusive rights in the European Union to Desitin ...